Allogene reported interim Phase 3 “off-the-shelf” CAR T data showing strong minimal residual disease clearance in first-line consolidation large B-cell lymphoma. In the Alpha3 futility analysis, seven of 12 patients in the cemacabtagene ansegedleucel (cema-cel) arm achieved MRD negativity at day 45 versus two of 12 in the observation arm. Allogene framed the result as a step toward validating donor-derived cell therapy as a more convenient alternative to individualized CAR T manufacturing. The company expects to complete enrollment and report full Phase 3 outcomes in 2027. The interim results also reported a manageable safety profile in the early analysis, with neurological side effects occurring but described as low grade in the report.